New drug treatment for pancreatic cancer 'extends survival'

Conclusion Pancreatic cancer is one of the toughest cancers to treat, with lower survival rates than many other cancers. Surgery is usually the first treatment, where possible. Some people also have chemotherapy or radiotherapy. Recent studies have looked into how different types of chemotherapy might help improve survival. This study shows that a combination of two chemotherapy drugs may help people live longer than taking one drug alone after surgery. But this doesn't mean everyone taking those drugs will survive at least five years, despite the media headlines. The researchers estimate 28.8%, or just over a quarter, of people who have surgery and take these two drugs will survive for at least five years. For people who don't live that long, the potential improvements in lifespan are much smaller. The average difference in survival time for those taking the drugs combination was 2.5 months. The downside is an increased chance of side effects from the chemotherapy drugs, which are usually taken for about six months. In these sorts of circumstances, people often have to make a tough choice about whether or not to pursue a treatment that may extend their life by only a few months, but could also worsen their quality of life. If you've been affected by cancer, find out more about cancer support services in your area. Links To The Headlines Trial finds combination of pancreatic cancer drugs extends survival. The Guardian, January 25 2017 Pancreatic cancer breakthrough '...
Source: NHS News Feed - Category: Consumer Health News Tags: Cancer Source Type: news